Pre-made Lacnotuzumab benchmark antibody ( Whole mAb, anti-CSF1 therapeutic antibody, Anti-MCSF/CSF-1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Lacnotuzumab biosimilar, Whole mAb, Anti-CSF1 Antibody: Anti-MCSF/CSF-1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lacnotuzumab, as known as MCS110, is a novel, high-affinity, humanized, anti-CSF-1 monoclonal antibody that prevents CSF-1 from activating the CSF-1R. The drug is being developed by Novartis Europharm Limited.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-289-1mg	1mg	3090
GMP-Bios-ab-289-10mg	10mg	Inquiry
GMP-Bios-ab-289-100mg	100mg	Inquiry
GMP-Bios-ab-289-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lacnotuzumab biosimilar, Whole mAb, Anti-CSF1 Antibody: Anti-MCSF/CSF-1 therapeutic antibody
INN Name	Lacnotuzumab
Target	CSF1
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2017
Companies	Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Seoul National University Hospital
Conditions Approved	na
Conditions Active	Breast cancer;Gastric cancer;Giant cell tumour of tendon sheath;Pigmented villonodular synovitis;Malignant melanoma;Solid tumours
Conditions Discontinued	Bone metastases;Prostate cancer
Development Tech	na